286 research outputs found
Judicial Analysis of Predation: The Emerging Trends
This Article examines the recent judicial experience in this endeavor. The purposes of the Article are twofold.The first is to describe the current state of the law regarding predation and to discern significant trends that may be developing. The second purpose is to explore the considerations that courts must weigh in evaluating the legal utility of proposed rules that may be valid as a matter of economic theory. Toward these ends,part II of the Article examines the economic and legal context in which litigants present predation claims. Specifically, this part re-views some of the academic debates that have so greatly influenced recent courtroom developments, the statutory framework within which these developments have occurred, and the legacy of Utah Pie Co. v. Continental Baking Co., which is the Supreme Court\u27s most recent predation decision. Part III then explores the standards that courts are applying in the three principal predation contexts-pricing, innovation, and promotion. Finally, part IV examines certain patterns of judicial analysis that are apparent in fifty-seven cases decided during and after 1975, the year in which Professors Areeda and Turner published their seminal article on predatory pricing. These patterns are important and predictive, for they reflect the courts\u27 views about both the frequency and competitive dangers of predation and the administrative costs of attempting to control it. This examination also includes a table summarizing the outcomes of these cases--who won, in which types of cases, at what procedural stage--and a discussion of some economic and administrative considerations underlying those outcomes.\u27 Overall, the analysis in this Article reveals both the legal trends in one specific area of antitrust law--predation-and, more broadly, the methods by which scholarly and judicial analyses can build upon one another to promote more rapid development of an evolving field of legal inquiry
Multicomponent geothermometry applied to a medium-low enthalpy carbonate-evaporite geothermal reservoir
Abstract To improve knowledge of the thermal state of medium to low-enthalpy thermal systems hosted in carbonate-evaporite rocks, a mineral-solution equilibrium model was compared to other theoretical geothermometers. We use the GeoT code, which uses as input the chemical composition of water and saturation indices of minerals to calculate water-rock equilibrium over a temperature range of interest. The calculations were applied to the medium and low enthalpy geothermal systems in the Tyrrhenian-Apennine area (central Italy). The lithology consists of a Paleozoic metamorphic basement, overlain by Mesozoic carbonateβevaporite- and OligoceneβMiddle Miocene flysch formations, and Quaternary volcanic complexes associated with crustal extension. A regional aquifer is hosted in the carbonate-evaporite formations, and smaller aquifers are hosted in the volcanic rocks. Reservoir temperatures were calculated based on the chemical composition of springs and wells in Central Italy (sampled previously), and in the Cimino-Vicano hydrothermal system (sampled in 2012). Chalcedony and quartz geothermometers provide realistic temperatures. The sensitivity of the model is tested for CO 2 degassing and input minerals. The results of optimized GeoT simulations show that all the samples are affected by degassing during their rise to the surface and that for computing a realistic reservoir temperature it is necessary to consider the principal minerals of the geothermal reservoir (particularly gypsum, quartz, dolomite, aragonite and calcite). The equilibrium temperatures range from 48-115 Β°C. The statistical approach of "best clustering minerals" solves the problems related to cation or single component geothermometers. Multicomponent geothermometry coupled with optimization provides a reliable approach to reconstruct fluid composition at depth and estimate reservoir temperatures
Bone Density in Children with Single Ventricle Physiology
Background
Children with chronic diseases are at risk for low bone mineral density (BMD). There are no studies of BMD in children with congenital heart disease and particularly SV. Children with this defect are often treated with warfarin, suspected to negatively impact BMD in adults. We assessed BMD in patients with single ventricle (SV) physiology and compared the BMD of subjects taking warfarin to those who were not.
Methods
Subjects 5-12 years with SV were included. BMD z-scores by dual-energy X-ray absorptiometry (DXA) of the spine and total body less head (TBLH) were obtained. Calcium intake, activity level, height, and Tanner stage were assessed. Linear regression models and t-tests were used to investigate differences between participants and normative data as well as between subjects' subgroups.
Results
Twenty six subjects were included; 16 took warfarin. Mean BMD z-score at the spine was significantly lower than expected at -1.0Β±0.2 (p<0.0001), as was the BMD z-score for TBLH at - 0.8Β±0.2 (p<0.0001). Those results remained significant after adjusting for height. Subjects who were on warfarin tended to have lower BMD at both the spine and TBLH than those who were not, with a z-score difference of 0.6Β±0.46 at the spine (p=0.106) and a difference of 0.4Β±0.34 at TBLH (p=0.132).
Conclusions
BMD is significantly reduced in children with SV. Warfarin appears to lower BMD but the effect is less conclusive. Continued evaluation is recommended for these patients at risk for reduced bone density. Evaluation of other cardiac patients on warfarin therapy should also be considered
Construction, alignment and analysis of twelve framework physical maps that represent the ten genome types of the genus Oryza
Bacterial artificial chromosome (BAC) fingerprint and end-sequenced physical maps representing the ten genome types of Oryza are presente
Amenability of groups and -sets
This text surveys classical and recent results in the field of amenability of
groups, from a combinatorial standpoint. It has served as the support of
courses at the University of G\"ottingen and the \'Ecole Normale Sup\'erieure.
The goals of the text are (1) to be as self-contained as possible, so as to
serve as a good introduction for newcomers to the field; (2) to stress the use
of combinatorial tools, in collaboration with functional analysis, probability
etc., with discrete groups in focus; (3) to consider from the beginning the
more general notion of amenable actions; (4) to describe recent classes of
examples, and in particular groups acting on Cantor sets and topological full
groups
Law professors want hearing, vote on Garland
Dear Senator Fischer and Senator Sasse,
We write this as citizens, but we all teach at the University of Nebraska College of Law. We hold different political viewpoints and disagree frequentIy with each other on political and legal issues. As law professors, however, we share a deep commitment to the rule of law and an impartial judiciary. We therefore urge you to hold confirmation hearings and a vote on President Obama\u27s Supreme Court nominee, Chief Judge Merrick B. Garland
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
Background: Preclinical studies suggest that chemotherapy may enhance the immune response against pancreatic cancer. Methods: The levels of granulocyte macrophage-colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6) and the associated inflammatory marker C-reactive protein (CRP) were assessed in 38 patients receiving gemcitabine and capecitabine combination chemotherapy for advanced pancreatic cancer within the TeloVac trial. Apoptosis (M30) and total immune response (delayed-type hypersensitivity and/or T-cell response) were also assessed and levels of apoptosis induction correlated with immune response. The telomerase GV1001 vaccine was given either sequentially (n=18) or concomitantly (n=24) with the combination chemotherapy. Results: There were no differences between baseline and post-treatment levels of CRP (P=0.19), IL-6 (P=0.19) and GM-CSF (P=0.71). There was a positive correlation between post-chemotherapy CRP and IL-6 levels (r=0.45, P=0.005) and between CRP with carbohydrate antigen-19-9 (CA19-9) levels at baseline (r=0.45, P=0.015) and post treatment (r=0.40, P=0.015). The change in CRP and IL-6 levels was positively correlated (r=0.40, P=0.012). Hazard ratios (95% CI) for baseline CA19-9 (1.30 (1.07β1.59), P=0.009) and CRP (1.55 (1.00β2.39), P=0.049) levels were each independently predictive of survival. The M30 mean matched differences between pre- and post-chemotherapy showed evidence of apoptosis in both the sequential (P=0.058) and concurrent (P=0.0018) chemoimmunotherapy arms. Respectively, 5 of 10 and 9 of 20 patients had a positive immune response but there was no association with apoptosis. Conclusions: Combination gemcitabine and capecitabine chemotherapy did not affect circulating levels of GM-CSF, IL-6 and CRP. Chemotherapy-induced apoptosis was not associated with the immunogenicity induced by the GV1001 vaccine in advanced pancreatic cancer
Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC
MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer
The role of microRNAs in small-cell lung carcinoma (SCLC) is largely unknown. miR-34a is known as a p53 regulated tumor suppressor microRNA in many cancer types. However, its therapeutic implication has never been studied in SCLC, a cancer type with frequent dysfunction of p53. We investigated the expression of a panel of 7 microRNAs (miR-21, miR-29b, miR-34a/b/c, miR-155, and let-7a) in 31 SCLC tumors, 14 SCLC cell lines, and 26 NSCLC cell lines. We observed significantly lower miR-21, miR-29b, and miR-34a expression in SCLC cell lines than in NSCLC cell lines. The expression of the 7 microRNAs was unrelated to SCLC patients' clinical characteristics and was neither prognostic in term of overall survival or progression-free survival nor predictive of treatment response. Overexpression or downregulation of miR-34a did not influence SCLC cell viability. The expression of these 7 microRNAs also did not predict in vitro sensitivity to cisplatin or etoposide in SCLC cell lines. Overexpression or downregulation of miR-34a did not influence sensitivity to cisplatin or etoposide in SCLC cell lines. In contrast to downregulation of the miR-34a target genes cMET and Axl by overexpression of miR-34a in NSCLC cell lines, the intrinsic expression of cMET and Axl was low in SCLC cell lines and was not influenced by overexpression of miR-34a. Our results suggest that the expression of the 7 selected microRNAs are not prognostic in SCLC patients, and miR-34a is unrelated to the malignant behavior of SCLC cells and is unlikely to be a therapeutic target
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
Hypertension is a mechanism-based toxic effect of drugs that inhibit the vascular endothelial growth factor signaling pathway (VSP). Substantial evidence exists for managing hypertension as a chronic condition, but there are few prospectively collected data on managing acute hypertension caused by VSP inhibitors. The Investigational Drug Steering Committee of the National Cancer Institute convened an interdisciplinary cardiovascular toxicities expert panel to evaluate this problem, to make recommendations to the Cancer Therapy Evaluation Program on further study, and to structure an approach for safe management by treating physicians. The panel reviewed: the published literature on blood pressure (BP), hypertension, and specific VSP inhibitors; abstracts from major meetings; shared experience with the development of VSP inhibitors; and established principles of hypertension care. The panel generated a consensus report including the recommendations on clinical concerns summarized here. To support the greatest possible number of patients to receive VSP inhibitors safely and effectively, the panel had four recommendations: 1) conduct and document a formal risk assessment for potential cardiovascular complications, 2) recognize that preexisting hypertension will be common in cancer patients and should be identified and addressed before initiation of VSP inhibitor therapy, 3) actively monitor BP throughout treatment with more frequent assessments during the first cycle of treatment, and 4) manage BP with a goal of less than 140/90 mmHg for most patients (and to lower, prespecified goals in patients with specific preexisting cardiovascular risk factors). Proper agent selection, dosing, and scheduling of follow-up should enable maintaining VSP inhibition while avoiding the complications associated with excessive or prolonged elevation in BP
- β¦